Chai 2 Signals a Leap in Custom Antibody Design

[kevin1]

Chai’s latest model, Chai 2, is showing major improvements in de novo antibody design, meaning it can create custom antibodies from scratch rather than tweaking existing ones. CEO Josh Meier says the models can design molecules with real drug-like properties and tackle previously unreachable targets—marking a meaningful step toward AI-designed medicines moving from theory to practice.

[Nahid Hossen]

AI-driven antibody design could dramatically shorten drug discovery timelines.